Zheng Quan Zhi Xing·2025-08-15 16:35Core Viewpoint - The company reported a slight increase in revenue but a decline in net profit, indicating challenges in the pharmaceutical industry due to competition and policy impacts [6][9]. Financial Performance - The company achieved operating revenue of RMB 41,834,546,114, a year-on-year increase of 1.93% [6][16]. - Total profit amounted to RMB 3,090,416,329, reflecting a decrease of 4.30% compared to the previous year [6][16]. - Net profit attributable to shareholders was RMB 2,517,000,000, with a decrease in cash flow from operating activities to RMB (3,397,136,268), down 66.79% year-on-year [6][13]. Business Development - The company focused on strengthening its pharmaceutical manufacturing chain, enhancing the development of traditional Chinese medicine and raw materials [6][7]. - Sales of key products such as Baijiu series and various health products showed significant growth, indicating a successful marketing strategy [7][9]. - The company expanded its international market presence, with products like Xiao Chai Hu Granules receiving registration in Macau [9][10]. Innovation and Digital Transformation - The company is advancing its digital transformation, implementing new ERP systems and S2B2C modules to enhance supply chain management [8][12]. - Continuous investment in research and development led to the approval of 15 new drug registrations during the reporting period [10][11]. Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.40 per share, totaling approximately RMB 650 million based on the total share capital [6][9]. - The total number of shareholders reached 85,550 by the end of the reporting period [13][17].